reports
Theralase® Releases FY2022 Audited Financial Statements
Theralase® Releases FY2022 Audited Financial Statements TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers released its audited annual consolidated 2022 financial statements. Financial Summary: For the year ended December 31st: Audited Consolidated Statements of Operations (...
Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at t...
Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that its Phase II clinical study (“Study II”) interim data was recently presented at the American S...
Theralase® Awarded TSX Venture 50™ Recognition as a Top Performing Com...
Theralase® Awarded TSX Venture 50™ Recognition as a Top Performing Company TORONTO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce it has been named to the ’s 2023 Venture 50™. The Venture 50™ is an annual ranking of the top-performing companies ...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presente...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that its Phase II Bacillus Calmette Guerin (“BCG”) Unresponsive Non-Muscle Invasive Bladder Cancer ...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presente...
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that its Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”) (I...
Theralase Releases Q322 Interim Financial Statements
Theralase Releases Q322 Interim Financial Statements TORONTO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses has released the Company’s unaudited 3Q2022 condensed interim consolidated Financial Statements (“Financial Statements”). Financial Highlights: ...
Theralase® Grants Stock Options
Theralase® Grants Stock Options TORONTO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, announces the grant of stock options. The Company has granted an aggregate of 7,860,000 stock options to directors, officers, employees & advisory board members pursuant to the ...
Theralase® Announces Warrant Extension
Theralase® Announces Warrant Extension TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date of 3,157,059 share purchase warrants, all of which are exercisable at $0.50 per share (collectively, the “Warrants”). The Warrants were i...
Theralase® Closes $2.5M Private Placement Equity Financing
Theralase® Closes $2.5M Private Placement Equity Financing TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that it has closed a non-brokered private placement offering (“Offering”) of units (“Units”). On closing, the Corporation issued ...
Theralase Releases Q222 Interim Financial Statements
Theralase Releases Q222 Interim Financial Statements TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s unaudited 2Q2022 condensed interim consolidated Financial Statements (“Financial Statements”). Financial Highlights: For the six-month period ended June...
Theralase Expands Intellectual Property Portfolio
Theralase Expands Intellectual Property Portfolio TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that the Company has expanded its Intellectual Property (“IP”) portfolio. Theralase® has recently been granted a Brazilian patent ...
Theralase® Research - One of the Top 10 Most Downloaded Papers
Theralase® Research - One of the Top 10 Most Downloaded Papers TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that Theralase®’s research, published in Translational Biophotonics (“TBIO”), is one of the top 10 most downloaded papers in TBIO, amongst work pub...
Theralase® Phase Ib NMIBC Clinical Study Published
Theralase® Phase Ib NMIBC Clinical Study Published TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that Theralase®’s Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) has been peer reviewed and published in the European Urology O...
Theralase Releases Q122 Interim Financial Statements
Theralase Releases Q122 Interim Financial Statements TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s unaudited 1Q2022 condensed interim consolidated Financial Statements (“Financial Statements”). Financial Highlights: For the three-month period ended Mar...
Theralase Release FY2021 Audited Financial Statements
Theralase Release FY2021 Audited Financial Statements TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers released its audited annual consolidated 2021 financial statements. Financial Highlights: For the years ended December 31st: Audited Consolidated Statements of Operations In Can...
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) 1 and their associated drug formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, has provided an update on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study (“Study II”). As previously ann...
Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Va...
Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine TORONTO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds1 (“PDC”) and their associated drug formulations intended for the safe and effective destruction of various cancers, bacteria and viruses, has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 (“COVID-19”) vaccine. In Au...
Theralase Expands Intellectual Property Portfolio
Theralase Expands Intellectual Property Portfolio TORONTO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that the Company has expanded its Intellectual Property (“IP”) portfolio. Theralase® has recently been granted an Indian patent for “Metal...
Theralase Releases 3Q21 Financial Statements and Newsletter
Theralase Releases 3Q21 Financial Statements and Newsletter TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses has released the Company’s unaudited 3Q2021 condensed interim consolidated Financial Statements (“Financial Statements”)...
Theralase Releases Q221 Unaudited Financial Statements and Quarterly N...
Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses has released the Company’s unaudited Q22021 condensed interim consolidated financial statements and Q...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.